IDA-FLAG chemo regimen effective for refractory AML and ALLInpharma Weekly -doi:10.2165/00128413-200615610-00026NoneSpringer International PublishingInpharma Weekly
The strategy for treating these patients is through reinduction chemo... G Specchia,D Pastore,P Carluccio,... - 《Annals of Hematology》 被引量: 101发表: 2005年 Ifosfamide, Idarubicin, and Etoposide in Relapsed/Refractory Hodgkin Disease or Non-Hodgkin Lymphoma: A Salvage Regimen with High ...
[ Keywords] advanced ovarian cancer;integrated traditional Chinese and Western medicine therapy;chemoradio- therapy regimen;Jianpi Jiedu Xiaoai prescription 卵巢癌是女性较常见的恶性肿瘤. 相关研究 1. 3 纳入标准 1) 符合上述西医诊断标准,明确 表明,2020 年我国卵巢癌新发病例数为 5. 5 万,占 诊断为...
School of Medical Imaging, Mudanjiang Medical University, Heilongjiang, Mudanjiang 157011, China [Abstract] Transcatheter arterial chemoembolization (TACE) is the most common regimen for the initial treatment of patients with unresectable liver cancer in China. Its limitation includes incomplete tumor ...
(PETHEMA) group designed a phase I–II trial using FLAG-Ida (fludarabine, idarubicin, cytarabine, and G-CSF) plus high-dose intravenous plerixafor, a molecule inducing mobilization of blasts through the SDF-1α-CXCR4 axis blockade and potentially leading to chemosensitization of the leukemic ...